NCT03580967View on ClinicalTrials.gov

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 1, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Type2 DiabetesMajor Depressive Disorder
Interventions
DRUG

Vortioxetine

Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Todd Doyle

OTHER

NCT03580967 - Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes | Biotech Hunter | Biotech Hunter